Related Experiment Video
Updated: Jun 12, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Dealing with the evidence dilemma in genomics and personalized medicine
1National Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. muk1@cdc.gov
Abstract:
In this commentary, I discuss how the promise of genomics and personalized medicine (GPM) is currently not matched by the evidence that supports its use in clinical practice. The mismatch between expectations and reality can be addressed by placing greater emphasis on multidisciplinary translation research and by stakeholder-driven collaboration that uses such research to address various and occasionally competing factors affecting the integration of genomic discoveries into clinical practice.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Genomics
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
